ReviewNature reviews. Gastroenterology & hepatology2026
Establishing cancer registries in Africa - focus on hepatopancreatobiliary cancers.
Review in Nature reviews. Gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990-2023: an analysis based on the Global Burden of Disease Study 2023.Journal of gastrointestinal oncology · 2026Article
- Building MASLD registries in the MENA region: From fragmented care to a learning health system.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Digital oncology frameworks in Africa: a scoping review of architectural patterns, digital maturity, and data equity implications.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatopancreatobiliary (HPB) cancers are a major cause of morbidity and mortality worldwide, particularly in Africa, where the risk factors, tumour characteristics, treatment-related factors and survival outcomes are poorly characterized. Despite the high incidence and mortality rates of HPB cancers in Africans, there is a dearth of data on the genetic and non-genetic risk factors for HPB cancers in Africa. The incidence and mortality rates of HPB cancers in Africans can only be substantially reduced by increasing our understanding of the population-specific risk factors and potentially unique underlying tumour biology. Pursuing this goal requires the establishment of robust clinical and population-based registries across the African continent for risk assessment, which will enable the development of strategies for HPB cancer prevention and implementation of surveillance programmes for early cancer detection in individuals at high risk. This goal was the premise for establishing the Africa HepatoPancreatoBiliary Cancer Consortium (AHPBCC). In this Roadmap article, we discuss the AHPBCC's collaborative efforts to increase knowledge about HPB cancers in Africans and to promote Africa-focused research on HPB cancers. We also provide in-depth discussions on the establishment of cancer registries in Africa, including the challenges, best practices and areas for growth, to improve HPB cancer outcomes in Africa.
Indexed as
Identifiers
41249658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.